(E)-[8]-Shogaol

(E)-Shogaol 是 Shogaol (MS-Q04635) 的异构体,而 Shogaol 是一种口服有效的凋亡 (apoptosis) 诱导剂和生长抑制剂,它通过促进促凋亡蛋白 Bad 表达、拮抗 Bcl-2 家族成员并激活 caspase 级联反应来诱导细胞凋亡,还能通过产生活性氧、耗竭谷胱甘肽并破坏线粒体跨膜电位来诱导自噬 (autophagy) 及内质网应激,同时抑制 LPS 介导的炎性细胞因子产生并使放射抵抗性胃癌细胞对放疗增敏,因此被广泛应用于白血病、结直肠癌、胃癌以及 LPS 诱导的脓毒症或炎症等相关研究。
产品编号: MS-U09786 CAS No.: 104186-07-4 分子式: C19H28O3 分子量: 304.42
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

(E)-Shogaol 是 Shogaol (MS-Q04635) 的异构体,而 Shogaol 是一种口服有效的凋亡 (apoptosis) 诱导剂和生长抑制剂,它通过促进促凋亡蛋白 Bad 表达、拮抗 Bcl-2 家族成员并激活 caspase 级联反应来诱导细胞凋亡,还能通过产生活性氧、耗竭谷胱甘肽并破坏线粒体跨膜电位来诱导自噬 (autophagy) 及内质网应激,同时抑制 LPS 介导的炎性细胞因子产生并使放射抵抗性胃癌细胞对放疗增敏,因此被广泛应用于白血病、结直肠癌、胃癌以及 LPS 诱导的脓毒症或炎症等相关研究。

生物实验数据

生物活性 (E)-Shogaol is an isomer of Shogaol (MS-Q04635), which is an orally active apoptosis inducer and growth inhibitor that induces apoptosis by promoting the expression of the pro-apoptotic protein Bad, antagonizing Bcl-2 family members, and activating the caspase cascade, and also induces autophagy and endoplasmic reticulum stress by generating reactive oxygen species, depleting glutathione, and disrupting the mitochondrial transmembrane potential, while inhibiting LPS-mediated inflammatory cytokine production and sensitizing radioresistant gastric cancer cells to radiotherapy, and is therefore widely used in research related to leukemia, colorectal cancer, gastric cancer, and LPS-induced sepsis or inflammation.
体外研究
(In Vitro)

-Shogaol (10-50 μM; 24 h) 可以浓度依赖的方式显著降低人早幼粒白血病 HL-60 细胞的存活率。
-Shogaol (10-50 μM; 24 h, 30 μM; 1-12 h) 可呈浓度和时间依赖性诱导人早幼粒细胞白血病 HL-60 细胞发生凋亡。
-Shogaol (30 μM; 1-12 h) 可激活 caspase-3、-8 和 -9 (但不激活 caspase-1),并以时间依赖的方式诱导人早幼粒细胞白血病 HL-60 细胞中的 PARP、DFF-45 和 D4-GDI 发生切割。
-Shogaol (15-25 μM; 24 h) 可在人结肠癌 HCT116 细胞中诱导浓度依赖性的 G2/M 期细胞周期阻滞,在 25 μM 浓度下有 58.10% 的细胞处于 G2/M 期,并调控细胞周期相关蛋白的表达。
-Shogaol (15-25 μM; 24 h) 可通过降低 p-AKT 和 p-PI3K 水平,以剂量依赖方式抑制人结肠癌 HCT116 细胞中的 PI3K/AKT 信号通路,并减弱 SC79 诱导的 AKT 磷酸化。

Cell Viability Assay

Cell Line: human promyelocytic leukemia HL-60 cells
Concentration: 10, 20, 30, 40, 50 μM
Incubation Time: 24 h
Result: Reduced HL-60 cell viability in a concentration-dependent manner.
Decreased cell viability to ~60% at 10 μM, ~45% at 20 μM, ~5% at 30 μM, and near 0% at 40 and 50 μM.
Showed statistically significant differences from control at all concentrations (P < 0.001).

Apoptosis Analysis

Cell Line: human promyelocytic leukemia HL-60 cells
Concentration: 10, 20, 30, 40, 50 μM (24 h incubation); 30 μM (1, 3, 6, 9, 12 h incubation)
Incubation Time: 24 h (10, 20, 30, 40, 50 μM); 1, 3, 6, 9, 12 h (30 μM)
Result: Increased percentage of apoptotic HL-60 cells (sub-G1 population) to 11.70% at 10 μM, 25.97% at 20 μM, 35.68% at 30 μM, 41.43% at 40 μM, and 43.67% at 50 μM after 24 h treatment.
Increased sub-G1 population to 6.19% at 1 h, 10.42% at 3 h, 31.43% at 6 h, 28.06% at 9 h, and 25.64% at 12 h with 30 μM treatment over time.

Cell Cytotoxicity Assay

Cell Line: human colon cancer HCT116 cells, normal human HEK293 cells
Concentration: 5-40 μM (MTT assay); 15-25 μM (morphological analysis)
Incubation Time: 24 h (MTT assay); null (morphological analysis)
Result: Exhibited a concentration-dependent inhibitory effect on HCT116 cells, with an IC50 value of 20.03 μM.
Showed minimal toxicity towards normal HEK293 cells.
Reduced HCT116 cell number and induced rounded, vacuolated morphology with increasing concentration.

Western Blot Analysis

Cell Line: human colon cancer HCT116 cells
Concentration: 15-25 μM (single treatment); 20 μM (co-treatment with SC79)
Incubation Time: 24 h
Result: Reduced p-AKT and p-PI3K expression in a concentration-dependent manner, while total AKT and PI3K expression remained relatively stable.
Attenuated SC79-induced p-AKT expression when co-treated with SC79.
体内研究
(In Vivo)

-Shogaol (20-40 mg/kg;口服;每日一次;连续 14 天) 在 Balb/c 裸鼠中展现出强效的剂量依赖性抗结直肠癌活性。
-Shogaol (30 mg/kg;腹腔注射;每周 2 次) 可在小鼠 LPS 诱导的脓毒症模型中使存活率提升约 4 倍,并降低促炎细胞因子 (TNF-α、IL-6、IL-1β) 的水平。
-Shogaol (30-60 mg/kg;腹腔注射;每周 2 次) 可显著抑制裸鼠体内 AGS 胃癌肿瘤的生长,且不会导致体重下降。

Animal Model: Balb/c female nude mice (5 weeks old)
Dosage: 20 mg/kg; 40 mg/kg
Administration: p.o.; daily; 14 days
Result: Reduced mean tumor volume to 0.585 cm3 and mean tumor weight to 0.942 g at 20 mg/kg.
Reduced mean tumor volume to 0.317 cm3 and mean tumor weight to 0.548 g at 40 mg/kg.
Induced reduced cell density, apoptotic cells, and necrotic regions in tumor tissue via H&E staining.
Increased apoptosis in a concentration-dependent pattern confirmed by TUNEL staining.
Reduced P-AKT expression and increased Beclin-1 expression in tumor tissue at 40 mg/kg.

化学信息

分子量 304.42
分子式 C19H28O3
CAS No. 104186-07-4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础